Mashup Score:273
medRxivRapid displacement of SARS-CoV-2 variant B.1.1.7 by B.1.617.2 and P.1 in the United States - 10 hours
Mashup Score:273
Articles from: medRxiv
Mashup Score:14
medRxivBroad Clinical Manifestations of Polygenic Risk for Coronary Artery Disease in the Women′s Health Initiative - 13 hours
Mashup Score:14
Background: The genetic basis for coronary artery disease (CAD) risk is highly complex. Genome-wide polygenic risk scores (PRS) can help to quantify that risk,...
-
No doubt, the most unexpected finding is the inverse relationship with higher polygenic risk for coronary artery disease being associated with decreased risk for cancer across several approaches. Check out the discussion for our thoughts 🤔 8/8 https://t.co/3i86jRupLV - view on twitter
Mashup Score:2
medRxivBackground: The genetic basis for coronary artery disease (CAD) risk is highly complex. Genome-wide polygenic risk scores (PRS) can help to quantify that risk,...
-
Would you guess that ⬆️ polygenic risk for coronary dz is associated w/ ⬇️ dietary health score in ♀️? Or ⬇️ Gail breast cancer risk score? Check out these & many other observations about polygenic risk for CAD in our #preprint now up on #medRxiv 1/n https://t.co/3i86jRupLV - view on twitter
Background REGEN-COV is a combination of 2 monoclonal antibodies (casirivimab and imdevimab) that bind to two different sites on the receptor binding domain of...
Mashup Score:47
medRxivPhase 1 Trial of Cyclosporine for Hospitalized Patients with COVID-19 - 1 day
Mashup Score:47
Coronavirus Disease 2019 (COVID-19) remains a global health emergency with limited treatment options, lagging vaccine rates and inadequate healthcare resources in the face of...
-
After over a year and 600,000 Americans dead, HERE R the results of a small phase 1 trial of CYCLOSPORINE 4 treatment of moderate to severe COVID-19 Disease. @TuckerCarlson @SenRonJohnson @DrWoodcockFDA @NIHDirector imagine how many could've been saved! https://t.co/HKCyrFCaSb - view on twitter
Mashup Score:128
medRxivRapid spread of the SARS-CoV-2 δ variant in the area of Paris (France) in June 2021 - 2 days
Mashup Score:128
Analysing 5,061 variant-specific tests performed on SARS-CoV-2 positive samples collected in France between 31 May and 8 June 2021 reveals a rapid growth of...
-
Delta comes to Paris, where the transmission advantage over Alpha is estimated to be higher than UK's https://t.co/TmMI6DcTZS And footnote: Previous tweet was intended to refer to fading of P.1 (Gamma) which until now was still growing in frequency https://t.co/TmMI6DcTZS - view on twitter
Mashup Score:33
medRxivIn this investigation we examined the magnitude, breadth, and durability of SARS-CoV-2 specific antibodies in two distinct B-cell compartments: long-lived plasma cell-derived antibodies in...
-
"more specific and what about these darn variants". Then I will tell you about this amazing paper published by OHSU recently which mildly says "Unease has arisen over the past several months with the emergence of specific CDC-defined variants of concern" https://t.co/kE5SN2Pbl3 - view on twitter
Mashup Score:3
medRxivVaccines against SARS-CoV-2 have shown high efficacy, but immunocompromised participants were excluded from controlled clinical trials. We evaluated immune responses to the Pfizer/BioNTech mRNA...
-
@SLentzsch Immune Responses to #COVID19 mRNA Vax in Pts w/ Solid Tumors on Immunosuppressive Cancer Tx [5/14/21] @rachnatshroff et al. @medrxivpreprint https://t.co/inleL4bEzO #COVID19nCancer #COVID19Vaccine #CCC19 3rd Vax might elevate Ab in CA Pts 2 levels seen in healthy after 2nd dose - view on twitter
Mashup Score:2
medRxivSuboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients - 3 days
Mashup Score:2
Studies describing SARS-CoV-2 immune responses following mRNA vaccination in hematology malignancy (HM) patients are virtually non-existent. We measured SARS-CoV-2 IgG production in 67 HM...
-
Suboptimal response to #COVID19 mRNA vaccines in hematologic malignancies Pts [Apr 7, 2021] Agha et al. @medrxivpreprint https://t.co/Cq2Afpc4N9 #COVID19Vaccine #COVID19nCancer #CCC19 #CLLsm #leusm #lymsm #mmsm #mpnsm MM (66%) > lymphoma (52%) > CLL (23%) Ab responses - view on twitter
-
@SLentzsch Suboptimal response to #COVID19 mRNA vaccines in hematologic malignancies Pts [Apr 7, 2021] Agha et al. @medrxivpreprint https://t.co/Cq2Afpc4N9 #COVID19Vaccine #COVID19nCancer #CCC19 #CLLsm #leusm #lymsm #mmsm #mpnsm MM (66%) > lymphoma (52%) > CLL (23%) Ab responses - view on twitter
Mashup Score:5
medRxivVaccines against SARS-CoV-2 have shown high efficacy, but immunocompromised participants were excluded from controlled clinical trials. We evaluated immune responses to the Pfizer/BioNTech mRNA...
-
Immune Responses to #COVID19 mRNA Vax in Pts w/ Solid Tumors on Immunosuppressive Cancer Tx [5/14/21] @rachnatshroff et al. @medrxivpreprint https://t.co/inleL4bEzO #COVID19nCancer #COVID19Vaccine #CCC19 3rd Vax might elevate Ab in CA Pts 2 levels seen in healthy after 2nd dose https://t.co/inleL4bEzO - view on twitter
The SARS-CoV-2 variant of concern B.1.617.2 displaced B.1.1.7 as the dominant variant in England and other countries. This study aimed to determine whether B.1.617.2...
Where is Delta (B.1.627.1) rapidly taking off in the United States? You get one guess https://t.co/ePOTk3ZWUR https://t.co/ePOTk3ZWUR - view on twitter